Form 4: Amgen CEO Robert Bradway Receives Major Equity Awards

Amgen Chairman and CEO Robert Bradway was granted over 91,000 equity units, including stock options and restricted stock, as part of his long-term compensation package.

Summary

• Robert A. Bradway, Chairman, CEO, and President of Amgen, received 12,136 Restricted Stock Units (RSUs) on May 5, 2026.
• Bradway was also granted 79,176 Non-qualified Stock Options with an exercise price of $329.59.
• Both the RSUs and the stock options are scheduled to vest in four equal annual installments of 25% each, beginning May 5, 2027.
• On May 6, 2026, 1,702 shares were withheld by the company to satisfy tax withholding obligations at a price of $329.59 per share.
• Following these transactions, Bradway directly owns 507,239 shares of Amgen common stock, which includes 1,520 dividend equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of executive alignment and stability, as the CEO receives significant performance-linked incentives.

Positives

• Significant equity grant of 91,312 total units aligns the CEO's financial interests with long-term shareholder value.
• The CEO maintains a very high level of direct ownership with over 500,000 shares held directly.
• The four-year vesting schedule encourages executive retention and long-term strategic focus.
• Indirect holdings through GRATs and a spouse total an additional 150,060 shares, showing broad family alignment with the company.

Negatives

• The disposal of 1,702 shares, while for tax purposes, represents a minor liquidation of equity at the current market price.

Risks

• The ultimate value of the 79,176 stock options is entirely dependent on the share price exceeding $329.59 over the next decade.
• Equity-based compensation is subject to market volatility and broader biotech sector risks.

Future Outlook

The grants indicate a long-term commitment to the current leadership, with vesting milestones extending through May 2030 and option expirations reaching into 2036.

Management Comments

• The Restricted Stock Units and stock options were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Industry Context

StockSavvy.ai notes that this level of equity compensation is standard for a large-cap biotechnology firm of Amgen's size, designed to compete for and retain executive talent in a highly specialized industry.

Comparison to Industry Standards

• The use of a four-year vesting period is consistent with industry peers such as Gilead Sciences and Biogen.
• The mix of RSUs and stock options is a common practice among S&P 500 healthcare companies to balance retention with performance incentives.
• Bradway's direct ownership stake is substantial compared to many peer CEOs, reflecting long-term tenure and confidence.

Stakeholder Impact

• Shareholders may view the large equity grant as a sign of the Board's confidence in the CEO's long-term strategic plan.
• Employees may see the continued leadership of Bradway as a sign of organizational stability.

Next Steps

• First 25% installment of the new grants will vest on May 5, 2027.
• Continued monitoring of insider transactions for further sentiment indicators.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation and does not fundamentally change the company's valuation or outlook, though it confirms management stability.

Keywords

Amgen, AMGN, Robert Bradway, Insider Trading, Executive Compensation, Stock Options, Restricted Stock Units, Form 4, Biotechnology